Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP4K4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP4K4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP4K4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP4K4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP4K4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAP4K4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP4K4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003350024 | Thyroid | ATC | carbohydrate homeostasis | 109/6293 | 259/18723 | 2.56e-03 | 1.18e-02 | 109 |
GO:000930623 | Thyroid | ATC | protein secretion | 146/6293 | 359/18723 | 2.83e-03 | 1.29e-02 | 146 |
GO:007132224 | Thyroid | ATC | cellular response to carbohydrate stimulus | 72/6293 | 163/18723 | 3.12e-03 | 1.41e-02 | 72 |
GO:003559223 | Thyroid | ATC | establishment of protein localization to extracellular region | 146/6293 | 360/18723 | 3.20e-03 | 1.44e-02 | 146 |
GO:004259325 | Thyroid | ATC | glucose homeostasis | 108/6293 | 258/18723 | 3.27e-03 | 1.47e-02 | 108 |
GO:000167825 | Thyroid | ATC | cellular glucose homeostasis | 75/6293 | 172/18723 | 3.89e-03 | 1.69e-02 | 75 |
GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
GO:007133324 | Thyroid | ATC | cellular response to glucose stimulus | 66/6293 | 151/18723 | 6.05e-03 | 2.43e-02 | 66 |
GO:01501462 | Thyroid | ATC | cell junction disassembly | 13/6293 | 21/18723 | 7.34e-03 | 2.87e-02 | 13 |
GO:00108127 | Thyroid | ATC | negative regulation of cell-substrate adhesion | 33/6293 | 68/18723 | 7.60e-03 | 2.97e-02 | 33 |
GO:005105114 | Thyroid | ATC | negative regulation of transport | 183/6293 | 470/18723 | 8.12e-03 | 3.13e-02 | 183 |
GO:007133124 | Thyroid | ATC | cellular response to hexose stimulus | 66/6293 | 153/18723 | 8.61e-03 | 3.28e-02 | 66 |
GO:005070815 | Thyroid | ATC | regulation of protein secretion | 109/6293 | 268/18723 | 8.87e-03 | 3.36e-02 | 109 |
GO:007132624 | Thyroid | ATC | cellular response to monosaccharide stimulus | 66/6293 | 154/18723 | 1.02e-02 | 3.71e-02 | 66 |
GO:003577313 | Thyroid | ATC | insulin secretion involved in cellular response to glucose stimulus | 34/6293 | 73/18723 | 1.45e-02 | 4.98e-02 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4K4 | SNV | Missense_Mutation | | c.3526N>T | p.Val1176Phe | p.V1176F | | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.3715N>C | p.Phe1239Leu | p.F1239L | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP4K4 | SNV | Missense_Mutation | | c.451N>T | p.His151Tyr | p.H151Y | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.643N>A | p.Asp215Asn | p.D215N | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.1246G>C | p.Glu416Gln | p.E416Q | | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.888) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.592N>A | p.Glu198Lys | p.E198K | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.673N>C | p.Glu225Gln | p.E225Q | | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.2322N>C | p.Leu774Phe | p.L774F | | protein_coding | tolerated_low_confidence(0.59) | probably_damaging(0.991) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.2741N>C | p.Gly914Ala | p.G914A | | protein_coding | tolerated_low_confidence(0.39) | probably_damaging(0.997) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP4K4 | insertion | Nonsense_Mutation | novel | c.1598_1599insGGAGGGTCAGACATAGACACAAGAGACGTAGAT | p.Asp533delinsGluGluGlyGlnThrTerThrGlnGluThrTerIle | p.D533delinsEEGQT*TQET*I | | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CYC-116 | CYC-116 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AST-487 | AST-487 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PD-0166285 | PD-0166285 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SB-220025 | SB-220025 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CEDIRANIB | CEDIRANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | OSI-632 | OSI-632 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AZD-1152-HQPA | AZD-1152-HQPA | |